How Gilead Sciences Stock Reacted to Its Q2 2026 Earnings, Measured Minute by Minute
Every earnings headline that crossed for Gilead Sciences on 4 August 2026, with the price reaction measured from the instant each line printed.
- Measured from the print at 20:00 UTC on 4 August 2026: $135.27 to $136.00 in fifteen minutes, +0.54%.
- Every headline row is measured from its own instant, so the lines can be compared directly.
- One-minute versus fifteen-minute readings show how fast the report was actually priced.
Reaction by asset (real prices)
| Asset | 2m before | At release | +1m | +15m | +1m % | +15m % |
|---|---|---|---|---|---|---|
| GILD | 135.27 | 135.27 | 134.01 | 136.00 | -0.93% | +0.54% |
Gilead Sciences reported, and the stock barely moved: +0.54% in the first fifteen minutes from 20:00 UTC. A flat print is information too — it says the result was already in the price.
This page is the measured anatomy of that print on 4 August 2026: every earnings-related headline that crossed for Gilead Sciences, in order, each with the price reaction measured from its own instant.
The print, row by row
| Crossed | Headline as recorded | 15-min move from that instant | Volume vs normal |
|---|---|---|---|
| 20:00 UTC | Gilead Sciences Inc. (GILD) Q2 2026 (USD) Adj. EPS -8.45 (exp. -7.26), Revenue 7.80bln (exp. 7.40bln) | +0.54% | — |
| 20:02 UTC | Gilead Sciences Raises FY2026 Adj EPS Guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) Est; Raises FY2026 Sales Guidance from $30.000B-$30. | +2.23% | — |
| 21:17 UTC | Gilead Sciences Exec Says Raising Full Year HIV Growth Expectations To 9%-10% YoY From Prior Guidance Of 8% Growth; Launch Preparations Fully Underway | -0.01% | — |
Which line actually moved it
Each row above is measured from its own instant — the price immediately before that specific headline crossed — so the rows can be compared directly. The largest single reaction, +2.23%, belongs to the 20:02 UTC line. By the time the 21:17 UTC line arrived, the measured response was -0.01% — the marginal information in each successive headline decays fast, and the decay is measurable.
Did the first read hold?
No — and that is the most useful fact on this page. The first fifteen minutes measured +0.54%, yet by the close of the next session the stock stood at -2.58% against the prior close. The instant reaction and the settled session disagreed about what this report was worth, which is exactly why both are worth measuring. A reader acting on the first print alone had the wrong sign.
A reaction this small after a scheduled report is its own finding: the result matched what the price already implied. For anyone tracking this name into next quarter, the useful comparison is whether the market stays this settled.
How these numbers were measured
We record the price of the instrument immediately before each headline crosses our news feed, then again one minute and fifteen minutes later, together with traded volume against that instrument's own normal. Every figure on this page comes from those recordings — the timestamps are the actual instants the lines crossed. Nothing here is an estimate, a close-to-close change, or a model's guess. The method, the gates every page must pass, and how we correct errors are documented in our editorial standards.
How did Gilead Sciences stock react to its Q2 2026 earnings?
Measured from the instant the first headline crossed on 4 August 2026 at 20:00 UTC, Gilead Sciences moved from $135.27 to $136.00 over the following fifteen minutes — +0.54%. The measurement starts at the print itself, not at the open, so it isolates the report's own effect.
How fast was the report priced in?
One minute after the print the measured move was -0.93%; at fifteen minutes it was +0.54%. The gap between those two figures is the pricing-in window — how long the market took to finish reading.
Which headline moved Gilead Sciences the most?
The 20:02 UTC line carried the largest measured reaction of the sequence at +2.23%. Later lines measured progressively less — repeat information decays within minutes.
Sources
-
Gilead Sciences Announces Second Quarter 2026 Financial Results - Gilead
Gilead reported Q2 2026 results on 4 August 2026: revenue up 10% to $7.8bn, an adjusted per-share loss of $6.75 against a $7.14 loss expected, HIV sales up 12%, and Biktarvy up 7% to $3.8bn.
-
Gilead Sciences Q2 2026 Earnings Call Transcript - Seeking Alpha
Gilead reported Q2 2026 results on 4 August 2026: revenue up 10% to $7.8bn, an adjusted per-share loss of $6.75 against a $7.14 loss expected, HIV sales up 12%, and Biktarvy up 7% to $3.8bn.
Never miss the next market-moving story
Follow the core market-moving feed across equities, macro, currencies and commodities. Your subscription includes price moves after the news, search, watchlists, alerts and research tools.
Create free accountGo real time Watch live headlines -- free